AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33881209
Drug: Prexasertib (LY2606368)
RxNorm normalized name: Prexasertib
DrugBank: Prexasertib (DB12008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prexasertib (LY2606368) administered intravenously on days 1 and 15 of a 28-day cycle at dose levels of 80, 100, 125, and 150 mg/m²
Trial: 33881718
Drug: Qishe Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishe Pill (3-4 g/kg for 4 weeks)
Trial: 33882147
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mycophenolic acid (MPA) use (adjusted for prior MPA discontinuation)
Trial: 33882846
Drug: Rilonacept (IL-1α/IL-1β
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilonacept (IL-1α/IL-1β cytokine trap) administered weekly during a 6-week base treatment period plus an optional 18-week extension period.
Trial: 33885369
Drug: Digital health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital health intervention (DHI) using animated health videos and InfoSpots; exposure to 3 different health animations once on a tablet device.
Trial: 33888901
Drug: Belzutifan (MK-6482)
RxNorm normalized name: belzutifan
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belzutifan (MK-6482) administered orally at 120 mg once daily in patients with ccRCC (n=55)
Trial: 33888901
Drug: Belzutifan (MK-6482)
RxNorm normalized name: belzutifan
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belzutifan (MK-6482) administered orally at various doses in dose-escalation cohort (n=43)
Trial: 33888901
Drug: Belzutifan (MK-6482)
RxNorm normalized name: belzutifan
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belzutifan (MK-6482) administered orally at various doses
Trial: 33891621
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care EoE treatment for 2 months
Trial: 33892111
Drug: Extended-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release methylphenidate (MPH-MLR)
Trial: 33892407
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg every 2 weeks) + Metronomic cyclophosphamide (25 mg/m2)
Trial: 33893210
Drug: HIV positive
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV positive subjects receiving antiviral treatment (32%)
Trial: 33893210
Drug: HIV negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV negative subjects receiving antiviral treatment (6%)
Trial: 33893289
Drug: Fulvestrant treatment
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant treatment
Trial: 33893692
Drug: Durvalumab (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1,500 mg every 4 weeks × 13) and Tremelimumab (75 mg Q4 weeks × 7, then Q12 weeks × 2)
Trial: 33895695
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to newly released anti-HER2 therapies (e.g. pertuzumab) from 2016 onwards
Trial: 33895874
Drug: Oral paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paromomycin and metronidazole
Trial: 33897579
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality intervention for motor and cognitive rehabilitation, details on dosage and duration not available.
Trial: 33898065
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant agents (OACs), including vitamin K antagonists (VKAs) and direct OACs (DOACs)
Trial: 33898065
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant agents (OACs)
Trial: 33898953
Drug: 3-monthly intramuscular
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3-monthly intramuscular depot medroxyprogesterone acetate (DMPA-IM)
Trial: 33898953
Drug: levonorgestrel (LNG)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: levonorgestrel (LNG) implant
Trial: 33900278
Drug: Angiopoietin-like protein
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiopoietin-like protein 3 inhibitors
Trial: 33901280
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of hyperthyroidism (restoration of euthyroidism)
Trial: 33901551
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at clinically administered doses using the Total Intravenous Anesthesia (TIVA/TCI) technique
Trial: 33902087
Drug: Adjunctive music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive music during ketamine infusion
Trial: 33902087
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion without music
Trial: 33902320
Drug: Acute Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute Daily Stress
Trial: 33902320
Drug: Daily Food
RxNorm normalized name: food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Food Consumption
Trial: 33903148
Drug: Pemafibrate (PPARα
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemafibrate (PPARα agonist)
Trial: 33903179
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue plasminogen activator (r-tPA), median dose 0.88 (IQR 0.78-0.90) mg/kg
Trial: 33903179
Drug: Urokinase (UK),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase (UK), median dose 1.71 (1.43-2.00)×10
Trial: 33904819
Drug: Community-based computerized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based computerized cognitive training (CCT) program, 10-week duration, 2-hour instructor-led group classes twice a week.
Trial: 33904821
Drug: Self-reported computerized
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported computerized history taking (CHT) on a tablet
Trial: 33905540
Drug: Drug therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapies that reduce gastric acidity
Trial: 37523175
Drug: Insulin-Only iLet
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-Only iLet Bionic Pancreas
Trial: 33907136
Drug: Self-acupressure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-acupressure therapy at acupoints TE17 (Yifeng), TE21 (Ermen), SI19 (Tinggong), and GB2 (Tinghui)
Trial: 33908631
Drug: Corticosteroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids and antibiotics
Trial: 33909232
Drug: Selinexor 60
RxNorm normalized name: selinexor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 60 mg once weekly in combination with intravenous topotecan
Trial: 33909232
Drug: Selinexor 80
RxNorm normalized name: SELINEXOR 80MG WEEKLY PKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 80 mg
Trial: 35911702
Drug: Treatment-related adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related adverse events (TRAE)
Trial: 33909934
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (real-world cohort)
Trial: 33910154
Drug: Larger right
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger right than left frontal alpha power prior to drug treatment in female patients.
Trial: 33910334
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy plus eltrombopag
Trial: 33910334
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy alone
Trial: 33910334
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy with or without eltrombopag
Trial: 33912461
Drug: Apatinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (250 mg orally per day) plus Camrelizumab (200 mg intravenously every three weeks)
Trial: 33912470
Drug: Sequential consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential consolidation with pembrolizumab for four cycles followed by nab-paclitaxel for four cycles (P→A)
Trial: 33912470
Drug: Concurrent nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent nab-paclitaxel and pembrolizumab for four cycles (AP)
Trial: 33912470
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of life measured by FACT-L
Trial: 33912799
Drug: escitalopram+golimumab (TNF-α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escitalopram+golimumab (TNF-α inhibitor)
Trial: 33912799
Drug: escitalopram+calcium tablet+vitamin
RxNorm normalized name: escitalopram Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escitalopram+calcium tablet+vitamin D (PKC activator)
Trial: 33912999
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of oxaliplatin
Trial: 33913086
Drug: Placebo switched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo switched to upadacitinib 15 mg once daily at week 24
Trial: 33913086
Drug: Placebo switched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo switched to upadacitinib 30 mg once daily at week 24
Trial: 33913104
Drug: ACV lip
RxNorm normalized name: ACV tripeptide
DrugBank: ACV tripeptide (DB02025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACV lip patch
Trial: 33913104
Drug: Placebo lip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lip patch
Trial: 33914097
Drug: Selinexor 100
RxNorm normalized name: selinexor 100 mg/week (20 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 100 mg weekly with FLAG-Ida
Trial: 33914097
Drug: Selinexor (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (60 mg, 80 mg, 100 mg weekly) with FLAG-Ida
Trial: 33914706
Drug: IFN-γ treatment
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-γ treatment
Trial: 35430299
Drug: anti-PD-1 therapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1 therapy
Trial: 33917922
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy de-escalation (ticagrelor replaced with clopidogrel)
Trial: 33919763
Drug: Novel Oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel Oral Liquid Formulation of 13-
Trial: 33920489
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (CP) infusion
Trial: 33921051
Drug: Single bronchodilation
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bronchodilation monotherapy
Trial: 33921166
Drug: Probiotic formulation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic formulation
Trial: 33921867
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (VKA) and Rivaroxaban
Trial: 33922654
Drug: Oral creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral creatine monohydrate (Cr) at a dose of 2 × 7 g per day for 2 months in conjunction with ongoing therapies
Trial: 33922654
Drug: Oral creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral creatine monohydrate (Cr) at a dose of 2 × 3-5 g per day for 3-6 months (proposed future study)
Trial: 33922654
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation as monotherapy or in conjunction with metformin (future potential use)
Trial: 33925513
Drug: Accelerometer-measured daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerometer-measured daily step counts (mean 10699.8 steps)
Trial: 33925513
Drug: Accelerometer-measured daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerometer-measured daily step counts
Trial: 33926412
Drug: Weight-management camp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-management camp followed by a community intervention (10-week program of weekly lifestyle education and physical activity sessions)
Trial: 33926503
Drug: Treatment indicated
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment indicated (surgery or targeted systemic therapy)
Trial: 33926797
Drug: Carbon nanoparticles
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon nanoparticles (CNs) injection (0.3 mL) into the fusion node prior to NAC.
Trial: 33926914
Drug: MORAb-202 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MORAb-202 (0.3 to 1.2 mg/kg intravenously once every three weeks)
Trial: 33927586
Drug: Mobile chat-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile chat-based support plus nicotine replacement therapy sampling (NRT-S)
Trial: 33929394
Drug: Anti-PD-1 Inhibitor
RxNorm normalized name: anti-inhibitor coagulant complex 1 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 Inhibitor
Trial: 33929874
Drug: BKV-specific cytotoxic
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKV-specific cytotoxic T lymphocytes (CTLs) infusion
Trial: 39186707
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan (SG) 10 mg/kg on days 1 and 8 of 21-day cycles
Trial: 33930223
Drug: Single-tablet combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-tablet combination of sofosbuvir (400 mg) and daclatasvir (30, 60, or 90 mg) for 12 or 24 weeks
Trial: 33931857
Drug: Bitopertin, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitopertin, a glycine transport inhibitor, administered orally, dosage and duration not available.
Trial: 33931953
Drug: Clinical inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical inhibitors of BCRP
Trial: 33932223
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec (± prandial insulin)
Trial: 33932223
Drug: Other basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other basal insulins (± prandial insulin)
Trial: 33933689
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to Daily Occupational Performance (CO-OP) intervention, 14 individual sessions
Trial: 33933719
Drug: First-episode antipsychotic-naïve
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-episode antipsychotic-naïve patients with schizophrenia
Trial: 33933719
Drug: First-episode antipsychotic-naïve
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-episode antipsychotic-naïve patients with schizophrenia and Healthy controls
Trial: 33933925
Drug: Conventional fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionated radiation therapy (CFRT)
Trial: 33933925
Drug: Postmastectomy hypofractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postmastectomy hypofractionated radiation therapy (HFRT)
Trial: 33934110
Drug: Pittsburgh Compound-B
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pittsburgh Compound-B (PiB) imaging
Trial: 33934351
Drug: MIV-mono (mivebresib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIV-mono (mivebresib at doses of 1.5, 2.0, or 2.5 mg)
Trial: 33934351
Drug: MIV-Ven (mivebresib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIV-Ven (mivebresib in combination with venetoclax at doses of 400 or 800 mg)
Trial: 33936110
Drug: Elevated TNFα
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elevated TNFα (median (IQR): 8.2 (6.4-9.8) pg/ml)
Trial: 33936110
Drug: Elevated IL-1β
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elevated IL-1β (0.21 (0.1-0.4) pg/ml)
Trial: 33937527
Drug: Gonadotropin-Releasing Hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-Releasing Hormone Agonists
Trial: 33937611
Drug: Self-efficacy intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-efficacy intervention for coping with breast cancer treatment
Trial: 33937624
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of somatic mutations of estrogen receptor alpha
Trial: 33937953
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg co-administered with modafinil 400 mg/day
Trial: 33937953
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg alone
Trial: 33937954
Drug: Lorlatinib (10-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib (10-200 mg orally once daily and twice-daily doses of 35, 75, and 100 mg in continuous 21-day cycles for phase I; 100 mg once daily in continuous 21-day cycles for phase II)
Trial: 33939006
Drug: Narrow diameter
RxNorm normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow diameter implants in T2DM patients (HbA1C > 6.5%)
Trial: 33939006
Drug: Narrow diameter
RxNorm normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow diameter implants in normo-glycemic patients (HbA1C < 6.0%)
Trial: 33939006
Drug: Narrow diameter
RxNorm normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow diameter implants in both groups
Trial: 33939067
Drug: DSP-7888 administered
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DSP-7888 administered intradermally (ID) at doses of 3.5 mg, 10.5 mg, and 17.5 mg.
Trial: 33939067
Drug: DSP-7888 administered
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DSP-7888 administered subcutaneously (SC) at doses of 3.5 mg and 10.5 mg.
Trial: 33939068
Drug: Savolitinib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib monotherapy 400 mg once daily (qd)
Trial: 33939068
Drug: Savolitinib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib monotherapy 600 mg qd
Trial: 33939068
Drug: Savolitinib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib 400 mg qd + Osimertinib 80 mg
Trial: 33939068
Drug: Savolitinib 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib 300 mg qd + Osimertinib 80 mg
Trial: 33939068
Drug: Savolitinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib 600 mg qd + Osimertinib 80 mg
Trial: 33940581
Drug: Telotristat ethyl
RxNorm normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telotristat ethyl (250 or 500 mg thrice daily)
Trial: 37486343
Drug: Rucaparib (PARP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib (PARP inhibitor)
Trial: 33941878
Drug: WNT974 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WNT974 (10 mg once-daily)
Trial: 33942031
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of biological therapy
Trial: 33942031
Drug: Treatment changes
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment changes due to the pandemic
Trial: 33942128
Drug: Ponatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib treatment
Trial: 33942298
Drug: Novel MYC-non-IG
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel MYC-non-IG fusion treatment